TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05366062
Drug: ERC1671
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
Study: NCT05366062
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
Study: NCT05701501
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was given placebo tablets of the same type based on the standard IBD treatment.
Study: NCT06413082
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
Study: NCT06450990
Drug: BGY-1601-VT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
Study: NCT05865002
Drug: AUR107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT00823693
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05255458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study: NCT05497453
Drug: Tyrosine kinase inhibitor One
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine Kinase Inhibitor
Study: NCT05497453
Drug: Checkpoint Inhibitor, Immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody that binds to PD-1 or PD-L1
Study: NCT05820191
Drug: Amyvid, Intravenous Solution
Normalized name: Amyvid, intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
Study: NCT05152498
Drug: Fu Zheng Jie Du Hua Yu therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
Study: NCT06552169
Drug: Arm 1: SOC (mTOR + CNI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.
Study: NCT06118398
Drug: Intravenous methylprednisolone (IVMP) and Efgartigimod
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)
Study: NCT06118398
Drug: IVMP
Normalized name: Intravenous Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP 800-1000mg/day for 3-5 days.
Study: NCT05959720
Drug: Intrathecal Suspension
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
Study: NCT05959720
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 D36 and D64
Study: NCT05959720
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2 D36 to D63 and D1 to D56 of consolidation
Study: NCT05959720
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.000 mg/m2 D8, D22, D36 and D50
Study: NCT05959720
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2 D1 and D22
Study: NCT05046561
Drug: STRI Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
Study: NCT05046561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT06210217
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
Study: NCT05928962
Drug: Recombinant Human Adenovirus Type 5 Injection
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Recombinant Human Type 5 Adenovirus Injection:~   This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~2. PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.
Study: NCT06204640
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
Study: NCT06214273
Drug: Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-inflammatory, topical analgesic and topical antifungal
Study: NCT04217304
Drug: Definity® with High Mechanical Index Ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
Study: NCT06208280
Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
Study: NCT04924881
Drug: COVID Rehab Formula granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID Rehab Formula granules once daily for 8 weeks
Study: NCT06246461
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
Study: NCT04978298
Drug: Rasigiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasigiline
Study: NCT00002013
Drug: AS-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05052801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06193434
Drug: IBI356 for MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive IBI356 in a multiple dose.
Study: NCT06193434
Drug: Placebo for SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive placebo in a single dose.
Study: NCT06193434
Drug: Placebo for MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive placebo in a multiple dose.
Study: NCT05179356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00915616
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05703009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05653869
Drug: APS03118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
Study: NCT06059144
Drug: Peripheral intravenous norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
Study: NCT05104775
Drug: GNC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion.
Study: NCT06386783
Drug: Fentanyl HCl
Normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
Study: NCT05463484
Drug: Test composition Saliactive® (olive product, betaine and xylitol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated toothpaste with Saliactive®.
Study: NCT05463484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated toothpaste without Saliactive®.
Study: NCT06139367
Drug: TQB3454 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
Study: NCT05569278
Drug: GE200486 0.5M Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
Study: NCT05493800
Drug: MIT-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding dose of MIT-001 IV injection during 0.5\~1hr
Study: NCT05493800
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline IV injection
Study: NCT05629260
Drug: Post-transplantation cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
Study: NCT04746495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
Study: NCT04746495
Drug: Eplerenone 50mg
Normalized name: EPLERENONE 50MG TAB
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
Study: NCT05868707
Drug: Salvage chemotherapy or best supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
Study: NCT05240391
Drug: Human Albumin 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
Study: NCT06395337
Drug: [111In]In-DOTA-ANTI-CEA antibody injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: tracer injection
Study: NCT05341141
Drug: ddEC-ddT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
Study: NCT04433988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05653856
Drug: 64Cu-PSMA I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled Receptor-Targeted Diagnostic Product
Study: NCT05864534
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
Study: NCT04857632
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 20mg per day for 7 days
Study: NCT05682196
Drug: standard of care treatment alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment alone
Study: NCT05632562
Drug: O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
Study: NCT04793958
Drug: mFOLFOX6 Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fluorouracil~* Oxaliplatin~* Folinic acid
Study: NCT04793958
Drug: FOLFIRI Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fluorouracil~* Irinotecan~* Folinic acid
Study: NCT04306510
Drug: Blood samples for immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
Study: NCT06555952
Drug: MegaNatural-BP SR 150Mg Tablet
Normalized name: MegaNatural-BP SR 150mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSE MegaNatural BP
Study: NCT05021861
Drug: Cyproterone Acetate, Ethinyl Estradiol Drug Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
Study: NCT05887492
Drug: TNG260
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoREST inhibitor, administered orally
Study: NCT05147259
Drug: HR011408 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
Study: NCT06564961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab once daily
Study: NCT06057467
Drug: Anticoagulation Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
Study: NCT06055452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant in the placebo group takes matching placebo.
Study: NCT05492682
Drug: PeptiCRAd-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive PeptiCRAd-1.
Study: NCT05492682
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be pre-treated with one single dose of Cyclophosphamide.
Study: NCT05979389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
Study: NCT04870203
Drug: anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history
Study: NCT04870203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg every 2 weeks during 6 months only during Period A
Study: NCT04931654
Drug: AZD7789
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Study: NCT04722627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel Assignment
Study: NCT04800172
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo tablet once daily for 3 months.
Study: NCT05866614
Drug: Remsima IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be treated with Remsima IV as per the SmPC or
Study: NCT05773170
Drug: Refralon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
Study: NCT05719701
Drug: ICP-490
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several dose groups of ICP-490 are planned for the dose exploration.
Study: NCT06521931
Drug: PN20
Normalized name: Lipram-PN20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
Study: NCT06287099
Drug: BRL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single infusion of BRL-101.
Study: NCT05562219
Drug: QA108 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take the medication as required for 24 weeks
Study: NCT05562219
Drug: QA108 granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take the medication as required for 24 weeks
Study: NCT00306826
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00306826
Drug: pioglitazone + simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05029778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive placebo 3g PO, for 24 h, until birth.
Study: NCT05641259
Drug: LP-108
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration for 21 or 28 days on a 28-day cycle
Study: NCT00261820
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04767529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT05004727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
Study: NCT06442111
Drug: The placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
Study: NCT05133310
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
Study: NCT04587427
Drug: Radium 223 dichloride (Xofigo, BAY88-8223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed by physicians.
Study: NCT00992472
Drug: Compazine® suppositories, 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05541107
Drug: MAT2203
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral lipid nanocrystal amphotericin B
Study: NCT05548270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Study: NCT06770491
Drug: Y-3 for injection
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd.
Study: NCT05263778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo by mouth once daily for 12 weeks
Study: NCT06455670
Drug: Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
Study: NCT05605886
Drug: Solvazinc 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
Study: NCT05605886
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00089869
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06116617
Drug: SRSD107
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
Study: NCT06116617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride